# Creating a registry of data of patients who have undergone endovascular reconstruction for aortic occlusive disease to assess treatment outcomes

Submission date 29/04/2020	<b>Recruitment status</b> No longer recruiting	<ul><li>Prospectively registered</li><li>Protocol</li></ul>
<b>Registration date</b> 05/05/2020	<b>Overall study status</b> Completed	<ul> <li>Statistical analysis plan</li> <li>Results</li> </ul>
Last Edited 05/05/2020	<b>Condition category</b> Circulatory System	<ul> <li>Individual participant data</li> <li>Record updated in last year</li> </ul>

#### Plain English summary of protocol

Background and study aims

Narrowing or blockages in the major arteries (aorto-iliac occlusive disease) can cause reduced blood flow to areas of the body leading to symptoms of pain (especially on movement) and tissue death (gangrene).

This is currently treated in Europe primarily using keyhole surgery techniques. These techniques are referred to as endovascular surgery. This may involve inserting a stent to keep the artery open for sufficient blood flow. The patient outcomes of these new techniques in treating blocked major arteries in the body are not well known.

Covered Endovascular Reconstruction of Aortic Bifurcation (CERAB) is a technique described to treat extensive aorto-iliac occlusive disease, especially in high risk patients. Despite promising outcomes from three years of research in cohorts from single hospitals, there is a lack of published results from other centres being able to reproduce these outcomes of this technique. Additionally, there are not currently results comparing the use of stent grafts (covered stents) and Bare Metal Stenting (BMS) for the endovascular treatment of aorto-iliac disease.

This study will look at the fate of patients who had this kind of treatment in many centres across Europe. The study aims to provide an understanding of what problems patients face following the surgeries and how optimal treatment can be provided.

#### Who can participate?

Information will be collected from patients who received treatment for aorto-iliac occlusive disease using endovascular surgery.

What does the study involve?

This is an observational trial. Patients will receive standard clinical care as per local policies and physicians' preference, and will not be required to attend any additional follow-up beyond standard care.

What are the possible benefits and risks of participating?

Only patients who have already had their surgery will be reported as part of this study. This project will have absolutely no impact on the clinical care of patients. No identifiable information will be collected and reported. There are no risks of participating as essentially the clinical care remains exactly the same.

Where is the study run from?

- 1. Guy's and St Thomas' NHS Foundation Trust (UK)
- 2. Leicester Vascular Institute (UK)
- 3. St Franziskus Hospital Münster (German)

When is the study starting and how long is it expected to run for? Information for patients who had their surgery from May 2016 to April 2020 will be collected and reported

Who is funding the study? This study is investigator-initiated and funded

Who is the main contact? Dr Hany Zayed hany.zayed@gstt.nhs.uk

### **Contact information**

**Type(s)** Scientific

**Contact name** Mr Hany Zayed

ORCID ID http://orcid.org/0000-0001-5023-5834

### Contact details

Vascular Surgery Department St Thomas' Hospital Westminster Road, 1st floor London United Kingdom SE1 7EH +44 02071887188 hany.zayed@gstt.nhs.uk

## Additional identifiers

### EudraCT/CTIS number

Nil known

#### **IRAS number**

**ClinicalTrials.gov number** Nil known

Secondary identifying numbers COBRA\_01

### Study information

#### Scientific Title

Covered Stents vs Bare Metal Stent Endovascular Reconstruction for Aortic Occlusive Disease (COBRA registry)

Acronym COBRA Registry

#### **Study objectives**

To describe the short and medium-term outcomes following Covered Endovascular Reconstruction of Aortic Bifurcation (CERAB) and compare these with the performance of Bare Metal Stenting (BMS) reconstructions in a multicentre registry.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

 NHS ethics approval not required as per HRA opinion March 2020, this registry does not impact on the pathway of clinical care and no identifiable data are collected. This is an observational study. Each centre outside the United Kingdom should seek all relevant approvals as per their local/national policies before commencing data collection of any description.
 Ethical approval will be sought locally in Germany (St. Franziskus Hospital in Muenster) but this had been delayed due to the current public health emergency.

#### Study design

International multicentre cohort study

**Primary study design** Observational

**Secondary study design** Cohort study

**Study setting(s)** Hospital

**Study type(s)** Treatment

#### Participant information sheet

No participant information sheet available

#### Health condition(s) or problem(s) studied

Aortoiliac steno-occlusive arterial disease with ischaemic pain at rest or when walking (claudication) or tissue loss (gangrene)

#### Interventions

This is an observational trial using retrospective data. Patients will receive standard clinical care as per best available evidence, local/regional/national care pathways, and physicians' preference using CERAB/endovascular treatment of aorto-iliac disease using a combination of covered stents and BMS in the aorta. Patients will not have any additional follow up, assessment or reporting to the investigators beyond standard clinical care. The surgical techniques and stents used, as well as patient outcome data, will be collected from clinician notes. No patient identifiable data will be collected or communicated.

#### Intervention Type

Device

**Phase** Not Applicable

#### Drug/device/biological/vaccine name(s)

A variety of BMSs and covered stents may be used as per local policies and physicians' preferences.

#### Primary outcome measure

Re-intervention-free-survival, defined as the composite endpoint of target lesion revascularization (TLR) and/or death, whichever occurred first, obtained from clinician notes collected at day of discharge from hospital, 30 days after the procedure, and latest available follow-up.

#### Secondary outcome measures

The following outcome measures will be obtained from clinician notes, collected at day of discharge from hospital, 30 days after the procedure, and latest available follow-up

- 1. Acute technical success
- 2. 30-days morbidity
- 3. 30-days mortality
- 4. Overall mortality
- 5. Conversion-to-surgery free time
- 6. Re-intervention free time

Overall study start date

01/02/2020

**Completion date** 30/04/2021

## Eligibility

#### Key inclusion criteria

Infrarenal chronic aorto-iliac occlusive/stenotic symptomatic disease for >14 Days
 Treatment by an aortic stent graft or bare metal stent with or without iliac stenting

Participant type(s)

Patient

#### Age group

Adult

**Sex** Both

#### Target number of participants

Observational study - no actual target.

#### Key exclusion criteria

- 1. Acute aortic occlusive disease
- 2. Aneurysm related interventions
- 3. Previous aorto-iliac stenting or In-Stent-Restenosis
- 4. Aortic coarctation
- 5. Isolated Kissing-Stent-Reconstruction without aortic stents
- 6. Aortic injury/trauma related interventions
- 7. Suprarenal/visceral segment reconstructions

#### Date of first enrolment

01/05/2016

### Date of final enrolment

30/04/2020

### Locations

**Countries of recruitment** Belgium

England

France

Germany

Greece

Italy

Netherlands

Spain

United Kingdom

#### Study participating centre

**Guy's and St Thomas' NHS Foundation Trust** Vascular Surgery Department St Thomas' Hospital Westminster Road, 1st floor London United Kingdom SE1 7EH

Study participating centre St Franziskus Hospital Münster Department of Vascular Surgery Hohenzollernring 70 Münster Germany 48145

**Study participating centre Leicester Vascular Institute** Glenfield Hospital Groby Road Leicester United Kingdom LR3 9QP

### Sponsor information

**Organisation** Guy's and St Thomas' NHS Foundation Trust

**Sponsor details** St Thomas' Hospital

Vascular Surgery Department North Wing Westminster Bridge Road London England United Kingdom SE1 7EH +44 02071887188 R&D@gstt.nhs.uk **Sponsor type** Hospital/treatment centre

Website http://www.guysandstthomas.nhs.uk/Home.aspx

**ROR** https://ror.org/00j161312

**Organisation** St. Franziskus Hospital

**Sponsor details** Hohenzollernring 70 Münster Germany 48145 +49 0251 9350 stavroulakis.konstantinos@yahoo.gr

**Sponsor type** Hospital/treatment centre

Website http://www.sfh-muenster.de/uk/home.html

ROR https://ror.org/051nxfa23

## Funder(s)

**Funder type** Other

Funder Name Investigator initiated and funded

## **Results and Publications**

**Publication and dissemination plan** Publication and dissemination intended in peer-reviewed journal, conferences, and online media.

#### Intention to publish date

30/01/2023

#### Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date

#### IPD sharing plan summary

Not expected to be made available